trial
as of 2026-07-01Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
NCTId NCT07615075
at a glance
Phase 4 · Not Yet Recruiting
Enrollment 40 (estimated)
Sponsored by University of Maryland, Baltimore County
Primary completion 2029-09-01
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Not Yet Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2026-09-01
Primary completion
2029-09-01
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Sponsors
University of Maryland, Baltimore CountyLead Sponsor
Investigators
1
Deanna L. Kelly, Pharm.D., BCPPPrincipal Investigator
Sites
1 total
Catonsville, United States
Facts & assertions
4 sourced
Enrollment
40
Phase
PHASE4
Primary Completion Date
2029-09-01
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator